

Supplementary File 1. Search String

The following searches were done on September 30, 2024:

Showing results for: **Glaucoma | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 09/27/2009 to 12/31/2023**

Showing results for: **Primary Open Angle Glaucoma \\\(POAG\\) | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 09/27/2009 to 12/31/2023**

Showing results for: **Angle-Closure Glaucoma | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 09/27/2009 to 12/31/2023**

Showing results for: **Glaucoma Open-Angle | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 09/27/2009 to 12/31/2023**

Showing results for: **Glaucoma Eye | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 09/27/2009 to 12/31/2023**

The following searches were done on August 10, 2025:

Showing results for: **Glaucoma | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 01/01/2024 to 12/31/2024**

Showing results for: **Primary Open Angle Glaucoma \\\(POAG\\) | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 01/01/2024 to 12/31/2024**

Showing results for: **Angle-Closure Glaucoma | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 01/01/2024 to 12/31/2024**

Showing results for: **Glaucoma Open-Angle | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 01/01/2024 to 12/31/2024**


Showing results for: **Glaucoma Eye | Completed studies | Phase: 2, 3, 4 | Interventional studies | Studies with results | Study start from 01/01/2024 to 12/31/2024**

Supplementary Table 1. Reporting Presence: RR and ARD (Publication vs Registry)

Reporting Presence	Registry reporting % (95% CI)	Publication reporting % (95% CI)	RR (95% CI)	ARD (95% CI)
SAE participants	100.0% (93.7, 100.0)	84.2% (72.1, 92.5)	0.84 (0.75–0.94)	-15.8% (-25.3%–-6.3%)
SAE total events	66.7% (52.9, 78.6)	77.2% (64.2, 87.3)	1.16 (0.92–1.46)	10.5% (-5.9%–26.9%)
OAE participants	100.0% (93.7, 100.0)	78.9% (66.1, 88.6)	0.79 (0.69–0.90)	-21.1% (-31.6%–-10.5%)
OAE total events	43.9% (30.7, 57.6)	94.7% (85.4, 98.9)	2.16 (1.60–2.92)	50.9% (36.8%–65.0%)
OAE frequency threshold	100.0% (93.7, 100.0)	56.1% (42.4, 69.3)	0.56 (0.45–0.71)	-43.9% (-56.7%–-31.0%)
Mortality	61.4% (47.6, 74.0)	42.1% (29.1, 55.9)	0.69 (0.47–0.99)	-19.3% (-37.3%–-1.3%)
Discontinuation due to AEs	78.9% (66.1, 88.6)	91.2% (80.7, 97.1)	1.16 (0.99–1.35)	12.3% (-0.6%–25.2%)

Notes: RR and ARD calculated on reporting presence (unpaired). 95% CIs use Katz (RR) and Wald (ARD).


Supplementary Figure 1. Traffic-light heatmap for ITT trials



Supplementary Figure 2. Traffic-light heatmap for PP trials

Per-protocol	Unique ID	Study ID	Experimental	Comparator	Outcome	Weight	D1	D2	D3	D4	D5	Overall
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												
												

Supplementary Figure 3. Risk of Bias 2.0 Summary of ITT trials



Supplementary Figure 4. Risk of Bias 2.0 Summary of PP trials

